All In Biotech

Drug Trial Radar · NCT04382755

Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure

A Prospective Randomized Open-label Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and Short-and Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure

Last checked: Nov 20, 2026Latest source record: Sep 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

81

Actual

Start

May 22, 2020

Primary completion

Dec 29, 2020

Study completion Apr 9, 2021

Sponsor

Lead sponsor
University Hospital, GhentAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
UCB Pharma
First posted
May 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized controlled, open-label trial comparing subcutaneous Zilucoplan® with standard of care to standard of care alone. In the active group, Zilucoplan® will be administered subcutaneously once daily for 14 days or till discharge from the hospital, whichever comes first. The hypothesis of the proposed intervention is that Zilucoplan® (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms, that lead to a 25% improvement in lung oxygenation parameters. This hypothesis is based on experiments performed in mice showing that C5a blockade can prevent mortality and prevent ARDS in mice with post-viral acute lung injury. Eligible patients include patients with confirmed COVID-19 infection suffering from hypoxic respiratory failure defined as O2 saturation below 93% on minimal 2l/min O2 therapy and/or ratio PaO2/FiO2 below 350.

Conditions

  • COVID-19

Interventions

  • Zilucoplan®Drug

    14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®

  • PlaceboDrug

    standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in OxygenationTime frame: at predose, day 6 and day 15 (or at discharge, whichever comes first)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • OLVZ Aalst

    Aalst, Belgium

  • AZ Sint Jan Brugge

    Bruges, Belgium

  • Erasmus University Hospital

    Brussels, Belgium

  • AZ Sint-Lucas

    Ghent, Belgium

  • University Hospital Ghent

    Ghent, Belgium

  • Jan Yperman Ziekenhuis Ieper

    Ieper, Belgium

  • University Hospital Liège

    Liège, Belgium

  • AZ Delta

    Roeselare, Belgium

  • AZ Vesalius

    Tongeren, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.